The Newsroom

Find out the latest about Calidi. Announcements, press coverage, publications, and company info—it’s all here.

Press Release

Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer

Calidi Biotherapeutics presents promising data on RTNova™, a novel systemic virotherapy technology designed to target metastatic lung cancer and other advanced cancers by overcoming immune clearance and enhancing therapeutic targeting

Discover More

Press Release

event

NeuroNova

Supernova

RTNova

Calidi Biotherapeutics Secures Series A Investments to Advance Manufacturing

January 22, 2020

Press Release

event

NeuroNova

Supernova

RTNova

The Mitchell Thorp Foundation Selects Calidi Biotherapeutics CEO to Receive the Pillars of Hope Award

December 19, 2019

Press Release

event

NeuroNova

Supernova

RTNova

Calidi Biotherapeutics Announces Appointment of Seasoned Biotech Executive George Ng to Board of Directors

October 9, 2019

Press Release

event

NeuroNova

Supernova

RTNova

Calidi Biotherapeutics Named One of the “50 Most Trustworthy Companies of The Year 2019” by the Silicon Review Magazine

September 18, 2019

Press Release

event

NeuroNova

Supernova

RTNova

Calidi Biotherapeutics is initiating GMP manufacturing at VetStem BioPharma, a veterinary and human regenerative medicine company in San Diego, CA

August 29, 2019

Publication

event

NeuroNova (NNV)

NeuroNova

Supernova

RTNova

First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells

The Journal of Translational Medicine

August 19, 2019

Press Release

Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Result

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, reports its financial results for the third quarter 2023 and reviews recent business highlights.

November 14, 2023

Discover More

Press Release

Calidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023)

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the presentation of new preclinical data from the company’s CLD-201 (SuperNova) allogeneic stem cell-based platform and announces readiness for clinical trial launch in 2024 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting. The meeting is taking place in San Diego from November 1-5, 2023.

November 3, 2023

Discover More

Press Release

Calidi Biotherapeutics Announces Key Leadership Promotions and New Board Appointment

November 1, 2023

Discover More

Press Release

Calidi Biotherapeutics Announces Appointment of Andrew Jackson as Chief Financial Officer

Calidi Biotherapeutics, Inc. (NYSEAM: CLDI) (or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the appointment of Andrew Jackson as Chief Financial Officer. Mr. Jackson is a financial executive with over 25 years of corporate finance experience with success in publicly traded companies and venture capital-backed startups.

October 30, 2023

Discover More

Press Release

Calidi Biotherapeutics To Present New Preclinical Data Highlighting Cell-based Virotherapy (SuperNova) Platform Technology at SITC 2023

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced a poster highlighting new preclinical data and clinical development plans from the company’s novel SuperNova technology will be presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting in San Diego, CA, taking place November 1-5, 2023.

October 10, 2023

Discover More

Press Release

Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the completion of its business combination with First Light Acquisition Group (FLAG), a special purpose acquisition company. The common stock and warrants of Calidi are expected to commence trading on the New York Stock Exchange American under the ticker symbols “CLDI” and “CLDI WS,” respectively, on September 13, 2023. The stockholders of FLAG approved the transaction on August 28, 2023, following approval by Calidi shareholders. Calidi’s existing management team, including Chief Executive Officer and Chairman Allan Camaisa, will lead the combined company.

September 13, 2023

Discover More

Publication

event

NeuroNova (NNV)

NeuroNova

Supernova

The Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting | November 7-11, 2018 Washington, D.C.

Abstract P609: First in man study of TK positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells

November 7, 2018

Publication

event

NeuroNova (NNV)

NeuroNova

Supernova

The Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting | November 7-11, 2018 Washington, D.C.

Abstract P617: A cell-based platform to protect and enhance oncolytic virus therapies

November 7, 2018

Publication

event

NeuroNova (NNV)

NeuroNova

Supernova

33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer | November 7-11, 2018 Washington, D.C.

November 7, 2018

Media

Scientific Advisory Board Member Interview - Ashok Srivastava, MD/PH.D.

February 3, 2024

Discover More

Media

Scientific Advisory Board Member Interview - W.K. Alfred Yung, MD

February 3, 2024

Discover More

Media

Scientific Advisory Board Member Interview - Bernard Fox, PhD,

February 3, 2024

Discover More

Media

Scientific Advisory Board Member Interview - Santosh Kesari, MD/PH.D.

February 3, 2024

Discover More

Media

Big Biz TV - Allan Camaisa

Pioneering Progress: Calidi Biotherapeutics CEO Allan Camaisa Unveils Latest Breakthroughs in Cancer Cure Research on Big Biz TV

December 4, 2023

Discover More

Media

Big Biz TV - Stephen Thesing

Pioneering Progress: Calidi Biotherapeutics CBO Stephen Thesing discusses the latest Breakthroughs in Cancer Cure Research on Big Biz TV

December 4, 2023

Discover More

In The News

Calidi Biotherapeutics: A Promising Player in the Cancer Treatment Market

Calidi Biotherapeutics Inc (NYSE: CLDI) is making waves in the biotech industry with its innovative approach to cancer treatment. The company utilizes allogeneic stem cells to deliver oncolytic viruses directly to tumors, offering new hope for patients.

October 9, 2023

Discover More

In The News

Analyst Bullish On Calidi Biotherapeutics, Newly Listed Cancer Treatment Player

Baird initiates coverage on Calidi Biotherapeutics Inc CLDI, which uses allogeneic stem cells to deliver oncolytic viruses to tumors for cancer treatment. Just a month back, Calidi Biotherapeutics became the latest biotech to take the special purpose acquisition company route to the public market

October 9, 2023

Discover More

A talented, seasoned group of world-class executives, doctors, and scientists producing revolutionary work.

Learn more

The Newsroom

Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer

Calidi Biotherapeutics Secures Series A Investments to Advance Manufacturing

The Mitchell Thorp Foundation Selects Calidi Biotherapeutics CEO to Receive the Pillars of Hope Award

Calidi Biotherapeutics Announces Appointment of Seasoned Biotech Executive George Ng to Board of Directors

Calidi Biotherapeutics Named One of the “50 Most Trustworthy Companies of The Year 2019” by the Silicon Review Magazine

Calidi Biotherapeutics is initiating GMP manufacturing at VetStem BioPharma, a veterinary and human regenerative medicine company in San Diego, CA

First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells

Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Result

Calidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023)

Calidi Biotherapeutics Announces Key Leadership Promotions and New Board Appointment

Calidi Biotherapeutics Announces Appointment of Andrew Jackson as Chief Financial Officer

Calidi Biotherapeutics To Present New Preclinical Data Highlighting Cell-based Virotherapy (SuperNova) Platform Technology at SITC 2023

Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies

The Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting | November 7-11, 2018 Washington, D.C.

The Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting | November 7-11, 2018 Washington, D.C.

33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer | November 7-11, 2018 Washington, D.C.

Scientific Advisory Board Member Interview - Ashok Srivastava, MD/PH.D.

Scientific Advisory Board Member Interview - W.K. Alfred Yung, MD

Scientific Advisory Board Member Interview - Bernard Fox, PhD,

Scientific Advisory Board Member Interview - Santosh Kesari, MD/PH.D.

Big Biz TV - Allan Camaisa

Big Biz TV - Stephen Thesing

Calidi Biotherapeutics: A Promising Player in the Cancer Treatment Market

Analyst Bullish On Calidi Biotherapeutics, Newly Listed Cancer Treatment Player

All Courses

A talented, seasoned group of world-class executives, doctors, and scientists producing revolutionary work.